WP 3: Development and GMP manufacturing of an off-the-shelf multi-epitope vaccine
WP 3 will focus on the definition, formulation, evaluation and GMP manufacturing of a multi-target, multi-epitope vaccine encompassing a broad range of HLA-alleles. Peptide candidates identified and selected in WP1 and WP2 will be compiled to generate the “off-the-shelf” HEPAVAC vaccine and make it available for the use in the proposed randomised, controlled, Phase I/II clinical trial (WP5). The combined HEPAVAC vaccine will be ready for application in the HEPAVAC clinical trial (WP5).
Leader: Christian Flohr, IMM